Peijian Peng

1.7k total citations
26 papers, 834 citations indexed

About

Peijian Peng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Peijian Peng has authored 26 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 12 papers in Otorhinolaryngology. Recurrent topics in Peijian Peng's work include Lung Cancer Treatments and Mutations (14 papers), Head and Neck Cancer Studies (12 papers) and Lung Cancer Research Studies (11 papers). Peijian Peng is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Head and Neck Cancer Studies (12 papers) and Lung Cancer Research Studies (11 papers). Peijian Peng collaborates with scholars based in China. Peijian Peng's co-authors include Shaodong Hong, Wenfeng Fang, Jianhua Zhan, Li Zhang, Lin Zhong, Lin Liu, Ting Zhou, Sheng Jin, Jiaxing Huang and Ying Chen and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Peijian Peng

23 papers receiving 831 citations

Peers

Countries citing papers authored by Peijian Peng

Since Specialization

Citations

This map shows the geographic impact of Peijian Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peijian Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peijian Peng more than expected).

Fields of papers citing papers by Peijian Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peijian Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peijian Peng. The network helps show where Peijian Peng may publish in the future.

Co-authorship network of co-authors of Peijian Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Peijian Peng. A scholar is included among the top collaborators of Peijian Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peijian Peng. Peijian Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interstitial lung disease following combined CDK4/6 inhibitor therapy and radiotherapy in advanced breast cancer: a case report 2025 ·Frontiers in Medicine ·Lanlan Guo, (unknown), (unknown), Zhiping Li, (unknown), (unknown), Xiaolu Xu, Peijian Peng	0
2	EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47 2024 ·Journal of Thoracic Oncology ·(unknown), Weitao Zhuang, (unknown), (unknown), Dongfang Wu, (unknown), Lanlan Pang, Yihua Huang, (unknown), (unknown), Peijian Peng, Jinxia Liang, Liangan Chen, Linjuan Zeng, (unknown), Wenfeng Fang	23
3	Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer 2021 ·Translational Lung Cancer Research ·(unknown), Yunpeng Yang, Peijian Peng, Jianhua Zhan, Zhihui Wang, (unknown), Zhonghan Zhang, Lin Liu, Wenfeng Fang, Li Zhang	23
4	<p>CD47 Overexpression Is Associated with Epstein–Barr Virus Infection and Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p> 2020 ·OncoTargets and Therapy ·Zhi‐Hui Wang, (unknown), (unknown), Lin Zhong, (unknown), Xiaolu Xu, (unknown), Li Zhang, Peijian Peng	12
5	Phase II Study of a Bi-Weekly Chemotherapy Regimen of Combined Liposomal Paclitaxel and Nedaplatin for the Treatment of Advanced Squamous Cell Lung Cancer 2019 ·Translational Oncology ·(unknown), Lin Zhong, Siyang Wang, (unknown), Zhi‐Hui Wang, (unknown), Xiaolu Xu, Peijian Peng	4
6	miR-429 suppresses cell proliferation, migration and invasion in nasopharyngeal carcinoma by downregulation of TLN1 2019 ·Cancer Cell International ·Zhihui Wang, (unknown), Lin Zhong, (unknown), Zibin Liang, (unknown), Jianxu Chen, Peijian Peng	23
7	Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial 2018 ·Translational Oncology ·Siyang Wang, (unknown), Ji‐Jin Yao, Peijian Peng, Bin Zhou, Qiaodan Liu, Xiaoping Huang, Lin Zhong	3
8	Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma 2017 ·Cancer Management and Research ·Lin Zhong, (unknown), Siyang Wang, (unknown), (unknown), Zhihui Wang, (unknown), Peijian Peng	6
9	Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer 2017 ·Journal of Cancer ·Wenfeng Fang, Ying Chen, Sheng Jin, Ting Zhou, Yaxiong Zhang, Jianhua Zhan, Lin Liu, Jiaxing Huang, Peijian Peng, Li Zhang	27
10	Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma 2017 ·BMC Cancer ·Lin Yang, Liangping Xia, Yan Wang, Shasha He, Haiyang Chen, Shaobo Liang, Peijian Peng, Shaodong Hong, (unknown)	16
11	KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma 2017 ·Cancer Immunology Immunotherapy ·Nan Chen, Wenfeng Fang, Lin Zhong, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Sheng Jin, Ting Zhou, Ying Chen, Hongyu Zhang, Li Zhang	236
12	Histologic lung cancer subtype differentiates synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases 2016 ·Journal of Surgical Research ·Hua Cheng, (unknown), Peijian Peng, Yujing Lin, Xiaojin Wang	27
13	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways 2016 ·BMC Cancer ·Lin Liu, Pei‐Yu Huang, Zhihui Wang, Nan Chen, (unknown), Lin Zhong, Peijian Peng	15
14	Low Prognostic Nutritional Index (PNI) Predicts Unfavorable Distant Metastasis-Free Survival in Nasopharyngeal Carcinoma: A Propensity Score-Matched Analysis 2016 ·PLoS ONE ·(unknown), Liangping Xia, Yan Wang, Shaodong Hong, Haiyang Chen, Shaobo Liang, Peijian Peng, Yong Chen	59
15	Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy 2015 ·Scientific Reports ·Lin Yang, Shaodong Hong, Yan Wang, Haiyang Chen, Shaobo Liang, Peijian Peng, Yong Chen	42
16	Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma 2015 ·Drug Design Development and Therapy ·Peijian Peng, (unknown), (unknown), Hai Liao, Lin Zhong, Yumeng Liu, Zhi‐Hui Wang, Siyang Wang, Zhibin Chen	11
17	Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis 2014 ·Drug Design Development and Therapy ·Peijian Peng, Hua Cheng, (unknown), Linjuan Zeng, Xuan Wu, Yumeng Liu, Lin Zhong, Yanna Tang, Siyang Wang, Hongyu Zhang, Zhibin Chen	12
18	Perineural Invasion and TAMs in Pancreatic Ductal Adenocarcinomas: Review of the Original Pathology Reports Using Immunohistochemical Enhancement and Relationships with Clinicopathological Features 2014 ·Journal of Cancer ·Linjuan Zeng, Yubo Guo, (unknown), Shaojie Chen, Peijian Peng, Qiubo Zhang, Hong Su, Yinting Chen, Kaihong Huang	34
19	Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy 2013 ·Cancer Chemotherapy and Pharmacology ·Peijian Peng, (unknown), Zhibin Chen, Hai Liao, (unknown), Siyang Wang, Hongyu Zhang, Lin Zhong	21
20	A randomized phase-II clinical control study on standard radiotherapy in combination with weekly oxaliplatin for treatment of loco-regional advanced nasopharyngeal carcinoma 2006 ·Clinical Oncology and Cancer Research ·Peijian Peng, Chong Zhao, Lixia Lu, Pei-Yu Huang, Fei Han, Shaoxiong Wu, Li Zhang	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact